Skip to main content
Aprogen Biologics Inc. logo

Aprogen Biologics Inc. — Investor Relations & Filings

Ticker · 003060 ISIN · KR7003060001 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2026-03-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 003060

About Aprogen Biologics Inc.

https://www.aprogen.com/en/v.do?a=Main

Aprogen Biologics Inc. is a biopharmaceutical company focused on the development and manufacturing of antibody-based therapeutics. The company's activities encompass two main areas: the creation of novel biologics and the production of biosimilars. Its pipeline of new drugs includes candidates for treating conditions such as blood vessel diseases and tumors. Simultaneously, Aprogen develops a portfolio of biosimilar products to offer alternatives to existing biologic medicines. The company operates significant manufacturing facilities to support the production of its biopharmaceutical products for both clinical trials and commercial supply.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 94% confidence The document is a detailed ‘주식등의 대량보유상황보고서’ – a mandatory report under the Capital Markets Act disclosing large shareholding positions, changes in ownership percentages, and related contract details. This matches the Major Shareholding Notification definition (MRQ) rather than a financial report or announcement of a meeting outcome.
2026-03-27 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) and covers the fiscal period from 2025-01-01 to 2025-12-31. It contains comprehensive financial and operational data, including company overview, business activities, capital structure, and production details. In the context of Korean regulatory filings (DART), a '사업보고서' is the equivalent of an Annual Report (10-K). FY 2025
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from Aprogen Biologics titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and auditor information. According to the 'Menu vs Meal' rule, this is an announcement of the filing of an audit report rather than the full audit report document itself, as it summarizes the results and provides a link to the official disclosure system (KIND). Therefore, it is classified as a Report Publication Announcement (RPA). FY 2025
2026-03-19 Korean
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집결의) filed by Aprogen Biologics. It details the agenda for an upcoming Annual General Meeting, including items such as financial statement approval, director appointments, and remuneration limits. This type of document is a standard proxy solicitation material used to inform shareholders of meeting details and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2026-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Aprogen Biologics. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and other corporate governance matters. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the meeting and vote on the proposed agenda items. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2026-03-13 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal notification filed with the Korea Exchange (KRX) regarding the company's decision to hold its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling and provides links to the actual AGM notice and resolution. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.